Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Allist Pharmaceuticals, Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05194995CT.gov JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Intestine Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jab-21822 (this asset) | Allist Pharmaceuticals, Inc. | P1/2 | CCC · 48 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Etoposide | Cancer Research UK | P2 | BB |
| Nivestim | Cancer Research UK | P2 | BB |
| Vincristine Sulfate | Cancer Research UK | P2 | BB |
| Adriamycin | Cancer Research UK | P2 | B |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| Prednisone | City of Hope Medical Center | P2 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | B |
+41 more in the Small Intestine Cancer cohort
Other indications for Jab-21822
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 56 |
| Neoplasm | — | P2 | CCC · 50 |
| Colorectal Cancer | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Jab-21822 in Small Intestine Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jab-21822-small-intestine-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →